A study to determine role in adjuvant immunotherapy era without lymphadenectomyin high risk stage III melanoma patients
Latest Information Update: 30 Jul 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Programmed cell death-1 ligand-1 inhibitors
- Indications Malignant melanoma
- Focus Therapeutic Use
- 30 Jul 2021 New trial record
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology